Table II.

Outcomes among resuscitated infants at 18–22 months by gestational age at birth and exposure to antenatal corticosteroids

Gestational age at birth	Outcome	ANS-exposed n (% [95% Cl])	No ANS n (% [95% CI])
22 weeks		N=21	N=57
	Survival	8 (38.1 [19.1–61.7])	10 (17.5 [9.5–30.1])
	Survival without severe impairment	6(28.6 [12.5–52.9])	6 (10.5 [4.7–22.0])
	Survival without moderate or severe impairment	4 (19.0 [6.7–43.6])	3 (5.3 [1.6–15.6])
23 weeks		N=347	N=172
	Survival	131 (37.8 [32.8–43.0])	42 (24.4 [18.5–31.5])
	Survival without severe impairment	102 (29.4 [24.8–34.4])	29 (16.9 [11.9–23.3])
	Survival without moderate or severe impairment	67 (19.3 [15.5–23.8])	16 (9.3 [5.7–14.7])
24 w eeks		N=955	N=102
	Survival	552 (57.8 [54.6–60.9])	46 (45.1 [35.6–55.0])
	Survival without severe impairment	454 (47.5 [44.4–50.7])	33 (32.4 [23.9–42.2])
	Survival without moderate or severe impairment	303 (31.7 [28.8–34.8])	24 (23.5 [16.2–32.9])
25 weeks		N=1058	N=117
	Survival	769 (72.7 [69.9–75.3])	81 (69.2 [60.2–77.0])
	Survival without severe impairment	648 (61.2 [58.3–64.1])	73 (62.4 [53.2–70.8])
	Survival without moderate or severe impairment	475 (44.9 [41.9–47.9])	48 (41.0 [32.4–50.3])
26 weeks		N=1072	N=143
	Survival	879 (82.0 [79.6–84.2])	112 (78.3 [70.7–84.4])
	Survival without severe impairment	818 (76.3 [73.7–78.8])	102 (71.3 [63.3–78.2])
	Survival without moderate or severe impairment	648 (60.4 [57.5–63.3])	64 (44.8 [36.7–53.1])